ENO2 and lung cancer: While our published primary analysis [13] did confirm the finding by Jacot et al [12] that baseline pre-treatment NSE level was prognostic for overall survival (HR 1.266, P = 0.0298), our study suggests that serum NSE is not a specific biomarker for lung cancer brain metastases and such further studies should not be pursued.